[Infliximab--practical guidelines for the treatment of Crohn's disease].
Infliximab is a monoclonal chimeric antibody, with high affinity and specificity for tumour necrosis factor alpha (TNFalpha) that plays a central role in the pathogenesis of immune mediated inflammatory disorders including Crohn's disease and ulcerative colitis. Globally over 600000 patients have been treated with infliximab to date. This global experience led to a better definition of the overall safety and efficacy profile of this medication. The goal of the present recommendations is to provide practical information to physicians involved in the care of patients with inflammatory bowel disease.
Bauerfeind
P
P
Division de Gastro-Entérologie et d'Hepatologie, CHUV, Lausanne. pierre.michetti@chuv.ch
Beglinger
C
C
Beltinger
J
J
Braegger
C
C
Eigenmann
F
F
Fried
M
M
Guyot
J
J
Hürlimann
R
R
Michetti
P
P
Seibold
F
F
Straumann
A
A
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab